CuraGen, Alexion Ink Drug-Target, Validation Alliance

Mar 12, 2002

NEW YORK, March 12 - CuraGen and Alexion Pharmaceuticals on Tuesday said they have signed a deal to discover and validate cancer-related biologic and small-molecule drug targets.

Terms of the multi-year agreement, which may grow in the future to include other diseases, call for CuraGen to apply its functional genomic technologies to help Alexion identify drug targets from data the biotech company will provide.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Breaking News

The Scan

Not a Unique Challenge Anymore

The US National Institutes of Health and the Food and Drug Administration have proposed changing gene therapy oversight, the Associated Press reports.

Case Goes On

Nature News reports that the Salk Institute has asked for the scope of a gender discrimination lawsuit brought against it to be narrowed.

The Very Old, Very Young, and Very Talented

CNBC reports that the sequencing startup Veritas aims to sequence individuals who fall at extremes.

This Week in PLOS

In PLOS this week: genotyping of indigenous North African goats, program to simulate evolve and resequencing studies, and more.

Main menu